Literature DB >> 32749950

Human Vaccines & Immunotherapeutics: news.

.   

Abstract

Entities:  

Year:  2020        PMID: 32749950      PMCID: PMC7482771          DOI: 10.1080/21645515.2020.1796189

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  5 in total

1.  Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.

Authors:  Neeltje van Doremalen; Teresa Lambe; Alexandra Spencer; Sandra Belij-Rammerstorfer; Jyothi N Purushotham; Julia R Port; Victoria A Avanzato; Trenton Bushmaker; Amy Flaxman; Marta Ulaszewska; Friederike Feldmann; Elizabeth R Allen; Hannah Sharpe; Jonathan Schulz; Myndi Holbrook; Atsushi Okumura; Kimberly Meade-White; Lizzette Pérez-Pérez; Nick J Edwards; Daniel Wright; Cameron Bissett; Ciaran Gilbride; Brandi N Williamson; Rebecca Rosenke; Dan Long; Alka Ishwarbhai; Reshma Kailath; Louisa Rose; Susan Morris; Claire Powers; Jamie Lovaglio; Patrick W Hanley; Dana Scott; Greg Saturday; Emmie de Wit; Sarah C Gilbert; Vincent J Munster
Journal:  Nature       Date:  2021-02       Impact factor: 49.962

2.  A Natural Peptide Antigen within the Plasmodium Ribosomal Protein RPL6 Confers Liver TRM Cell-Mediated Immunity against Malaria in Mice.

Authors:  Ana Maria Valencia-Hernandez; Wei Yi Ng; Nazanin Ghazanfari; Sonia Ghilas; Maria N de Menezes; Lauren E Holz; Cheng Huang; Kieran English; Myo Naung; Peck Szee Tan; Kirsteen M Tullett; Thiago M Steiner; Matthias H Enders; Lynette Beattie; Yu Cheng Chua; Claerwen M Jones; Anton Cozijnsen; Vanessa Mollard; Yeping Cai; David G Bowen; Anthony W Purcell; Nicole L La Gruta; Jose A Villadangos; Tania de Koning-Ward; Alyssa E Barry; Winfried Barchet; Ian A Cockburn; Geoffrey I McFadden; Stephanie Gras; Mireille H Lahoud; Patrick Bertolino; Ralf B Schittenhelm; Irina Caminschi; William R Heath; Daniel Fernandez-Ruiz
Journal:  Cell Host Microbe       Date:  2020-05-11       Impact factor: 21.023

3.  A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates.

Authors:  V M Stone; M M Hankaniemi; O H Laitinen; A B Sioofy-Khojine; A Lin; I M Diaz Lozano; M A Mazur; V Marjomäki; K Loré; H Hyöty; V P Hytönen; M Flodström-Tullberg
Journal:  Sci Adv       Date:  2020-05-06       Impact factor: 14.136

4.  T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.

Authors:  Prabhu S Arunachalam; Tysheena P Charles; Vineet Joag; Venkata S Bollimpelli; Madeleine K D Scott; Florian Wimmers; Samantha L Burton; Celia C Labranche; Caroline Petitdemange; Sailaja Gangadhara; Tiffany M Styles; Clare F Quarnstrom; Korey A Walter; Thomas J Ketas; Traci Legere; Pradeep Babu Jagadeesh Reddy; Sudhir Pai Kasturi; Anthony Tsai; Bertrand Z Yeung; Shakti Gupta; Mark Tomai; John Vasilakos; George M Shaw; Chil-Yong Kang; John P Moore; Shankar Subramaniam; Purvesh Khatri; David Montefiori; Pamela A Kozlowski; Cynthia A Derdeyn; Eric Hunter; David Masopust; Rama R Amara; Bali Pulendran
Journal:  Nat Med       Date:  2020-05-11       Impact factor: 53.440

5.  Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.

Authors:  Feng-Cai Zhu; Yu-Hua Li; Xu-Hua Guan; Li-Hua Hou; Wen-Juan Wang; Jing-Xin Li; Shi-Po Wu; Bu-Sen Wang; Zhao Wang; Lei Wang; Si-Yue Jia; Hu-Dachuan Jiang; Ling Wang; Tao Jiang; Yi Hu; Jin-Bo Gou; Sha-Bei Xu; Jun-Jie Xu; Xue-Wen Wang; Wei Wang; Wei Chen
Journal:  Lancet       Date:  2020-05-22       Impact factor: 202.731

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.